DE60131975T2 - Anwendung des herpes simplex virus glykoproteins-d zur unterdrückung von immunantworten - Google Patents

Anwendung des herpes simplex virus glykoproteins-d zur unterdrückung von immunantworten Download PDF

Info

Publication number
DE60131975T2
DE60131975T2 DE60131975T DE60131975T DE60131975T2 DE 60131975 T2 DE60131975 T2 DE 60131975T2 DE 60131975 T DE60131975 T DE 60131975T DE 60131975 T DE60131975 T DE 60131975T DE 60131975 T2 DE60131975 T2 DE 60131975T2
Authority
DE
Germany
Prior art keywords
protein
nucleic acid
vector
individual
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60131975T
Other languages
German (de)
English (en)
Other versions
DE60131975D1 (de
Inventor
David B. Merion WEINER
Jeong Im Seocho-ku SIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania
Original Assignee
University of Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania filed Critical University of Pennsylvania
Application granted granted Critical
Publication of DE60131975D1 publication Critical patent/DE60131975D1/de
Publication of DE60131975T2 publication Critical patent/DE60131975T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DE60131975T 2000-07-27 2001-07-27 Anwendung des herpes simplex virus glykoproteins-d zur unterdrückung von immunantworten Expired - Fee Related DE60131975T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22102500P 2000-07-27 2000-07-27
US221025P 2000-07-27
PCT/US2001/023648 WO2002010410A1 (en) 2000-07-27 2001-07-27 Compositions for and methods of using herpes simplex virus glycoprotein d to suppress immune responses

Publications (2)

Publication Number Publication Date
DE60131975D1 DE60131975D1 (de) 2008-01-31
DE60131975T2 true DE60131975T2 (de) 2008-12-18

Family

ID=22826021

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60131975T Expired - Fee Related DE60131975T2 (de) 2000-07-27 2001-07-27 Anwendung des herpes simplex virus glykoproteins-d zur unterdrückung von immunantworten

Country Status (8)

Country Link
US (1) US7569218B2 (enExample)
EP (1) EP1305435B1 (enExample)
JP (1) JP2004505113A (enExample)
AT (1) ATE381351T1 (enExample)
AU (2) AU8467201A (enExample)
CA (1) CA2417364A1 (enExample)
DE (1) DE60131975T2 (enExample)
WO (1) WO2002010410A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120027841A1 (en) * 2004-01-07 2012-02-02 Biomedical Research Models, Inc. Novel mucosal vaccination approach for herpes simplex virus type-2
US7717271B2 (en) * 2005-12-07 2010-05-18 General Electric Company Membrane structure and method of making
US20070131609A1 (en) * 2005-12-08 2007-06-14 General Electric Company Membrane structure and method of making
US8207854B2 (en) * 2009-02-09 2012-06-26 Mach 1 Development, Inc. Shipping container integrity device and system
RU2585961C9 (ru) * 2009-05-22 2016-12-27 Дженосеа Биосайенсиз Инк. Вакцины против вируса простого герпеса 2 типа: композиции и способы запуска иммунного ответа
JP6055776B2 (ja) 2010-11-24 2016-12-27 ジェノセア バイオサイエンシーズ， インコーポレイテッド 単純ヘルペスウイルス２型に対するワクチン：免疫応答を誘発する組成物及び方法
JP6199878B2 (ja) 2011-11-23 2017-09-20 ジェノセア バイオサイエンシーズ， インコーポレイテッド 単純ヘルペスウイルス２型に対する核酸ワクチン：免疫応答を誘発する組成物及び方法
EP3519427A4 (en) 2016-09-28 2020-03-11 Genocea Biosciences Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF HERPES
MX2023008826A (es) 2021-02-01 2023-09-15 Regenxbio Inc Terapia génica para lipofuscinosis neuronal ceroidea.

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4241046A (en) 1978-11-30 1980-12-23 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
DK0737750T3 (da) 1989-03-21 2003-09-01 Vical Inc Ekspression af exogene polynucleotidsekvenser i vertebrater
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5955088A (en) 1992-02-03 1999-09-21 Cedars-Sinai Medical Center Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), glycoproteins
ATE295895T1 (de) 1992-03-11 2005-06-15 Powderject Vaccines Inc Genetischer impfstoff gegen den immunschwäche virus
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
WO1994027612A1 (en) * 1993-05-20 1994-12-08 Baylor College Of Medicine Genetic therapy for cardiovascular disease
US5614503A (en) 1993-11-12 1997-03-25 Aronex Pharmaceuticals, Inc. Amphipathic nucleic acid transporter
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
WO1995033835A1 (en) * 1994-06-02 1995-12-14 Chiron Corporation Nucleic acid immunization using a virus-based infection/transfection system
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
IT1270123B (it) * 1994-10-05 1997-04-28 Dompe Spa Composizioni farmaceutiche contenenti microorganismi ingegnerizzati e loro uso per terapia
US5707618A (en) 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy
US5756283A (en) 1995-06-05 1998-05-26 The Trustees Of The University Of Pennsylvania Method for improved production of recombinant adeno-associated viruses for gene therapy
JP2002514056A (ja) 1996-10-23 2002-05-14 アメリカン・ホーム・プロダクツ・コーポレーション ワクチン
WO1999043839A1 (en) * 1998-02-27 1999-09-02 The Trustees Of The University Of Pennsylvania Vaccines, immunotherapeutics and methods for using the same

Also Published As

Publication number Publication date
AU8467201A (en) 2002-02-13
CA2417364A1 (en) 2002-02-07
US7569218B2 (en) 2009-08-04
US20040014705A1 (en) 2004-01-22
DE60131975D1 (de) 2008-01-31
EP1305435B1 (en) 2007-12-19
JP2004505113A (ja) 2004-02-19
WO2002010410A1 (en) 2002-02-07
EP1305435A1 (en) 2003-05-02
AU2001284672B2 (en) 2007-05-24
ATE381351T1 (de) 2008-01-15
EP1305435A4 (en) 2004-06-16

Similar Documents

Publication Publication Date Title
DE69331762T2 (de) "heat shock"-proteine und behandlung von tumoren
DE69836643T2 (de) Zusammensetzungen für die zufuhr von genen an antigen-präsentierende zellen der haut
DE60309513T2 (de) Substanzen zur Vorbeugung und Behandlung von Autoimmunkrankheiten
DE69522562T2 (de) Eine glucagon enthaltende pharmazeutische zubereitung
EP3132043B1 (de) Viraler vektor für den zielgerichteten gentransfer in gehirn und rückenmark
DE69927262T2 (de) Cd40 bindende antikörper und ctl peptide zur behandlung von tumoren
DE69706593T2 (de) Verwendung von Plasmiden zur Herstellung eines Impfstoffs bei Mensch und Tier
DE69715000T2 (de) Verabreichung von gm-csf zur behandlung der gehirntumoren und verhütung deren wiederauftretens
DE60024791T2 (de) Antigen-spezifische induktion der peripheren immuntoleranz
DE69632967T2 (de) Verfahren zur Verhinderung der Transplantabstoßung bei einer Transplantation und zur Herstellung einer universalen Gentherapie-Wirtszelle unter Anwendung von Lymphocyten-Aktivierungsgen (LAG-3)
EP0777499A1 (de) Lebendvakzine zur behandlung von tumorerkrankungen
DE19917195B4 (de) Peptid zur Auslösung einer Immunreaktion gegen Tumorzellen, diese enthaltende pharmzeutische Zusammensetzungen, dessen Verwendungen, dafür codierende Nukleinsäure und diese Nukleinsäure enthaltender Expressionsvektor
WO2004035799A2 (de) Virale vektoren und deren verwendung für die gentherapie
DE69627644T2 (de) Vektoren, die therapeutische gene fuer antimikrobielle peptide enthalten, zur verwendung in der gentherapie
US7569218B2 (en) Compositions for and methods of using herpes simplex virus glycoprotein D to suppress immune responses
DE60107888T2 (de) Beta-Interferon zur Behandlung von Immunerkrankungen
AU2001284672A1 (en) Compositions for and methods of using herpes simplex virus glycoprotein D to suppress immune responses
DE69427188T2 (de) Zusammensetzung zur behandlung von tumoren und immunisierung von organismen gegen tumore
DE69728654T2 (de) Verwendung von il-7 zur behandlung von autoimmunkrankheiten, insbesondere insulinabhängigem diabetes mellitus
DE69428984T2 (de) Stimulierung der immunantwort durch virales protein
EP1409534A2 (de) Pharmazeutische zusammensetzung zur behandlung und prophylaxe von humanen tumoren, die das tumorantigen muzin und/oder das carcinoembryonale antigen (cea) exprimieren und ihre verwendung
DE69221605T2 (de) Nicht-zellzahlverringernde cd4-spezifische monoklonale antikörper zur behandlung von insulinabhängigem diabetes mellitus (iddm)
EP1068331A1 (de) Arzneimittel zur induktion zytotoxischer t-zellen
EP1425303A2 (de) Verwendung eines proteins zur herstellung eines medikaments zur stimulierung des angeborenen unspezifischen immunsystems
DE60316407T2 (de) Tumornekrosefaktor in kombination mit interferon zur behandlung und/oder verhinderung einer demyelinisierenden krankheit

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee